United States - English - NLM (National Library of Medicine)

pharmaberg inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - - open the flip. - pull out wipes one by one & use. - please reseal after use to prevent moisture loss. for hand sanitizing to decrease bacteria on the skin. recommended for repeated use. do not push fingers through opening antiseptic

United States - English - NLM (National Library of Medicine)

pharmaberg inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m), benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y), phenoxyethanol (unii: hie492zz3t) (phenoxyethanol - unii:hie492zz3t), didecyldimonium chloride (unii: jxn40o9y9b) (didecyldimonium - unii:z7f472xqpa), chlorphenesin (unii: i670dal4sz) (chlorphenesin - unii:i670dal4sz), cetylpyridinium chloride (unii: d9om4sk49p) (cetylpyridinium - unii:cub7ji0jv3) - antiseptic for hand sanitizing to decrease bacteria on the skin. recommended for repeated use. do not push fingers through opening. read product label carefully before use.if you have a hypersensitivity to any of the components of the formula, do not use the product.

United States - English - NLM (National Library of Medicine)

pharmaberg inc. - didecyldimonium chloride (unii: jxn40o9y9b) (didecyldimonium - unii:z7f472xqpa), benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y), chlorphenesin (unii: i670dal4sz) (chlorphenesin - unii:i670dal4sz), alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m), phenoxyethanol (unii: hie492zz3t) (phenoxyethanol - unii:hie492zz3t), cetylpyridinium chloride (unii: d9om4sk49p) (cetylpyridinium - unii:cub7ji0jv3) - antiseptic for hand sanitizing to decrease bacteria on the skin. recommended for repeated use. do not push fingers through opening. read product label carefully before use.if you have a hypersensitivity to any of the components of the formula, do not use the product.

United States - English - NLM (National Library of Medicine)

pharmaberg inc. - cetylpyridinium chloride (unii: d9om4sk49p) (cetylpyridinium - unii:cub7ji0jv3), didecyldimonium chloride (unii: jxn40o9y9b) (didecyldimonium - unii:z7f472xqpa), benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y), chlorphenesin (unii: i670dal4sz) (chlorphenesin - unii:i670dal4sz), phenoxyethanol (unii: hie492zz3t) (phenoxyethanol - unii:hie492zz3t), alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic for hand sanitizing to decrease bacteria on the skin. recommended for repeated use. do not push fingers through opening read product label carefully before use.if you have a hypersensitivity to any of the components of the formula, do not use the product.

United States - English - NLM (National Library of Medicine)

pharmaberg inc. - phenoxyethanol (unii: hie492zz3t) (phenoxyethanol - unii:hie492zz3t), chlorphenesin (unii: i670dal4sz) (chlorphenesin - unii:i670dal4sz), cetylpyridinium chloride (unii: d9om4sk49p) (cetylpyridinium - unii:cub7ji0jv3), didecyldimonium chloride (unii: jxn40o9y9b) (didecyldimonium - unii:z7f472xqpa), alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m), benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - (bag) 1. open the flip. 2. pull out wipes one by one & use. 3. please reseal after use to prevent moisture loss (canister) 1. open the lid of the container. tear open the foil. 2. thread first sheet in center of roll through slits in lid. replace lid. 3. pull out wipes one by one & use. please reseal after use to prevent moisture loss antiseptic for hand sanitizing to decrease bacteria on the skin. recommended for repeated use. do not push fingers through opening. read product label carefully before use.if you have a hypersensitivity to any of the components of the formula, do not use the product.

United States - English - NLM (National Library of Medicine)

pharmaberg inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic - to decrease bacteria on the skin that could cause disease. - recommended for repeated use. stop use and ask a doctor if - irritation or redness develop. - condition persists for more than 72 hours

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; dichloromethane; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmacor moxclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmacor moxclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmacor moxclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.c

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: isopropyl alcohol; magnesium stearate; dichloromethane; colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmacor clavam tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmacor clavam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmacor clavam tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; dichloromethane; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmacor clavam tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmacor clavam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmacor clavam tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - pregabalin, quantity: 150 mg - capsule, hard - excipient ingredients: purified talc; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pharmacor pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pharmacor pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.